ZymoGenetics Inc.

Dr. Bruce L.A. Carter was appointed as an Additional Director on the Board of the Company effective July 21, 2008. Dr. Carter is the Chairman of the Board and the Chief Executive Officer of ZymoGenetics, Inc. Seattle, Washington, USA. Dr. Carter was appointed Chairman of ZymoGenetics in April, 2008 and has been the Chief Executive Officer of ZymoGenetics, Inc. since April, 1998. He joined ZymoGenetics in 1986 first as Vice-President of Research and Development. In 1994, he was chosen as Corporate Executive Vice-President and Chief Scientific Officer for Novo Nordisk A/S, the former parent company of Zymogenetics. He was elected to the Board of ZymoGenetics in 1987 and was appointed President of the company in 1998. Dr. Carter led the negotiations that established Zymogenetics as an independent company from Novo Nordisk in 2000. Dr. carter held various positions of increasing responsibility at G.D.Searle & Co. Ltd. from 1982-1986 and was a lecturer at Trinity College, University of Dublin from 1975-1982. Dr. Carter is a B.Sc. Botany (Honors) from University of Nottingham, England, and a Ph.D. in Microbiology from Queen Elizabeth College, University of London.

Stephen W. Zaruby has served as President of ZymoGenetics since January 2, 2009. Previously Mr. Zaruby served as Vice President, Global Head, Hospital/Surgical Business Unit, Haematology/Cardiology, with Bayer HealthCare Pharmaceuticals. In that role, he was the global strategic and U.S. operational head for hospital, surgical and related specialty products. Prior to that, he served as Director, Global Strategic Marketing for Bayer HealthCare Pharmaceuticals, where he oversaw global strategic marketing and commercialization platforms for the quinolone franchise. Previously, Mr. Zaruby held several other sales, marketing and product development positions within Bayer HealthCare and its affiliates. Mr. Zaruby earned a B.S. with Honors in Cellular, Molecular, and Microbiology from the University of Calgary in Calgary, Alberta.

Vaughn Himes joined Seattle Genetics in April 2009, bringing more than twenty years of experience in manufacturing, technical operations, process development and scale-up activities. As Executive Vice President, Technical Operations, he oversees Seattle Genetics' manufacturing, supply chain and quality assurance and control functions. Previously, Dr. Himes was with Zymogenetics, Inc., most recently as Senior Vice President, Technical Operations where his responsibilities included commercial and clinical manufacturing, supply chain and logistics, quality control and process development. While at Zymogenetics, he oversaw the chemistry, manufacturing and control (CMC) portion of the successful Biologics License Application for Recothrom and managed its commercial supply. Previously, he held Vice President positions in manufacturing and development at Corixa, Targeted Genetics and Genovo. Dr. Himes received a Bachelor of Arts in Chemistry from Pomona College in California and a Ph.D. in Chemical Engineering from the University of Minnesota.

David H. MacCallum has been one of our directors since June 2004. Currently, Mr. MacCallum is the Managing Partner of Outer Islands Capital, a hedge fund specializing in health care investments. From June 1999 until November 2001, he was Global Head of Health Care investment banking for Salomon Smith Barney, part of Citigroup, a financial institution. Prior to joining Salomon Smith Barney, he was Executive Vice President and Head of the Health Care group at ING Barings Furman Selz LLC, an investment banking firm and subsidiary of ING Group, a Dutch financial institution, from April 1998 to June 1999. Prior to that, Mr. MacCallum formed the Life Sciences group at UBS Securities, an investment banking firm, where he was Managing Director and Global Head of Life Sciences from May 1994 to April 1998. Before joining UBS Securities, he built the health care practice at Hambrecht & Quist, an investment banking firm, where he was Head of Health Care and Co-Head of Investment Banking. Mr. MacCallum received an A. B. degree from Brown University and an M.B.A. degree from New York University. He is a Chartered Financial Analyst.

Array